Lymphocyte Engineering for Therapeutic Synthetic Immunity
Adoptive T cell therapy has advanced to become a distinguished and rapidly evolving translational research field in modern medicine. This collaborative research center (CRC) transregio (TRR) LETSIMMUN is setting out to become a hot spot for cutting-edge basic and translation research in Lymphocyte Engineering in Germany, and aspires to deliver novel concepts and cell products for clinical development that provide Therapeutic Synthetic Immunity for patients.
LETSimmun is committed to improving the gender gap in science and taking actions against any form of disadvantages and discrimination. More
CAR-T cells at work: in vivo imaging of CAR T cells in Primary CNS Lymphoma